PE20212367A1 - Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas - Google Patents

Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Info

Publication number
PE20212367A1
PE20212367A1 PE2021001691A PE2021001691A PE20212367A1 PE 20212367 A1 PE20212367 A1 PE 20212367A1 PE 2021001691 A PE2021001691 A PE 2021001691A PE 2021001691 A PE2021001691 A PE 2021001691A PE 20212367 A1 PE20212367 A1 PE 20212367A1
Authority
PE
Peru
Prior art keywords
solid
plasma concentrations
enhanced performance
achieve therapeutic
therapeutic plasma
Prior art date
Application number
PE2021001691A
Other languages
English (en)
Spanish (es)
Inventor
Robert J Garmise
Jaquan Kalani Levons
Jay Poorna Reddy
Kevin Stefanski
Vrushali M Waknis
Theresa M Ziemba
Ajay Saxena
Srikanth Koravady Sridhar
Gajendra Singh Chowan
Sharmistha Pal
Shabeerali Pattasseri
Roopa Narasimhamurthy
Narayan Swamy Panduranga
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20212367A1 publication Critical patent/PE20212367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2021001691A 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas PE20212367A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
PE20212367A1 true PE20212367A1 (es) 2021-12-21

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001691A PE20212367A1 (es) 2019-04-11 2020-04-10 Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas

Country Status (17)

Country Link
EP (1) EP3953355A1 (enExample)
JP (2) JP2022526656A (enExample)
KR (1) KR20210151183A (enExample)
CN (1) CN113924300A (enExample)
AR (1) AR118650A1 (enExample)
AU (1) AU2020271103A1 (enExample)
BR (1) BR112021020257A2 (enExample)
CA (1) CA3132530A1 (enExample)
CL (1) CL2021002627A1 (enExample)
CO (1) CO2021015054A2 (enExample)
EA (1) EA202192753A1 (enExample)
IL (1) IL287103A (enExample)
MX (2) MX2021012288A (enExample)
PE (1) PE20212367A1 (enExample)
SG (1) SG11202111131VA (enExample)
TW (1) TW202104228A (enExample)
WO (1) WO2020210629A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304561A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
KR20240060820A (ko) 2021-09-17 2024-05-08 브리스톨-마이어스 스큅 컴퍼니 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안
JP2025525915A (ja) 2022-08-01 2025-08-07 ブリストル－マイヤーズ スクイブ カンパニー 虚血性脳卒中を処置又は予防するためのミルベクシアンの使用
WO2024167899A1 (en) 2023-02-06 2024-08-15 Bristol-Myers Squibb Company Milvexian pharmaceutical compositions
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224249A1 (en) 1985-11-27 1987-06-03 Syntex (U.S.A.) Inc. Amorphous benzimidazole derivatives
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (enExample) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
AR118650A1 (es) 2021-10-20
TW202104228A (zh) 2021-02-01
IL287103A (en) 2021-12-01
BR112021020257A2 (pt) 2021-12-07
JP2022526656A (ja) 2022-05-25
EA202192753A1 (ru) 2022-01-11
AU2020271103A1 (en) 2021-12-02
US20220144835A1 (en) 2022-05-12
CA3132530A1 (en) 2020-10-15
WO2020210629A1 (en) 2020-10-15
CO2021015054A2 (es) 2021-11-19
MX2025011559A (es) 2025-11-03
CN113924300A (zh) 2022-01-11
EP3953355A1 (en) 2022-02-16
SG11202111131VA (en) 2021-11-29
CL2021002627A1 (es) 2022-05-06
KR20210151183A (ko) 2021-12-13
MX2021012288A (es) 2021-11-12
JP2025131625A (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
PE20212367A1 (es) Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CY1122626T1 (el) Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα
MX2019006881A (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
MX2019011491A (es) Formulaciones de niraparib.
DOP2009000278A (es) Derivados de bencimidazol
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
ECSP15051434A (es) Composición farmacéutica de dosis baja
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2024006019A (es) Derivado de pirrol o sales farmacéuticamente o sitológicamente aceptables del mismo, y composición para prevención, mejoramiento o tratamiento de trastornos gastrointestinales que comprende el mismo como ingrediente activo.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX394367B (es) Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
MX341356B (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы